Protein Chromatography Resin Patents: Who Leads, Trends 2026
- Filings have cooled from their 2020 peak. 143 records that year against 84 in 2021 and 66 in 2024, a -21% slide over that three-year span — not a collapse, but a market past its filing surge.
- No single company controls the field. The leader holds 188 records and the top 5 combined account for just 14.5% of all 3,831 records in scope, with a long tail of 100 ranked assignees behind them.
- Separation-process claims sit inside a peptide-heavy field. 73.5% of records touch C07K peptide/protein chemistry, while B01D separation processes (42.1%) and B01J catalysis/process claims (27.8%) trail behind it — resin engineering is filed alongside the biology, not instead of it.
Filing growth compares 2021 (84 records) with 2024 (66) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 3,831 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Protein chromatography resin selection sits at the intersection of separation engineering and protein chemistry: binding capacity, ligand density, resin lifetime, protein selectivity, pressure limits and alkaline stability are the parameters that decide whether a resin survives repeated cleaning cycles in a commercial bioprocess train. This landscape draws on 3,831 published records filed or published between 2015 and mid-2026 that combine affinity or chromatographic purification claims with at least one of those operating parameters, classified under B01D15/08, C07K1/16 or C12N9/00.
Publication lags filing by roughly 18 months, so the 2025 and 2026 counts in the trend chart understate real activity in those years and should not be read as a slowdown on their own.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology mix
Two views of the same 3,831 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017-2026
Filings rose to a peak of 143 in 2020, then eased to 84 in 2021 and 66 in 2024 — a -21% change over that span. The most recent years are still filling in under publication lag and should be read with that in mind rather than as evidence of a declining field.
Technology composition by IPC subclass
C07K (peptides and proteins) appears in 73.5% of records, ahead of C12N genetic engineering (46.2%) and B01D separation processes (42.1%). Because a single record can carry several IPC codes, these shares sum well past 100% and should be read against the 3,831-record total, not against each other.
Shares are the percentage of the 3,831 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Protein Chromatography Resin Selection with Eureka
This page is one run against one query. Ask Eureka your own question about protein chromatography resin selection and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Sterile affinity chromatography resin — US10071364B2 (Genzyme Corporation, 2018-09-11)
The patent covers methods of reducing bioburden of a chromatography resin by exposing a container holding the resin plus at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to sterilise it, where the antioxidant/chelator amount is calibrated to offset the binding-capacity loss that gamma exposure otherwise causes. It also covers the resulting reduced-bioburden resin and columns built from it.Abstract text drawn directly from the granted claim record; full claim scope should be checked against the file wrapper before relying on it.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2005052146A2 | Serine proteases, nucleic acids encoding serine enzymes and vectors and host cells incorporating same | 1,591 |
| 2 | WO1999064619A2 | Novel mannanases | 813 |
| 3 | WO2004003186A2 | Subtilases and subtilase variants having altered immunogenicity | 794 |
| 4 | US20050100543A1 | Multivalent carriers of bi-specific antibodies | 727 |
| 5 | WO1992014843A1 | Aptamer specific for biomolecules and method of making | 609 |
| 6 | US5429746A | Antibody purification | 489 |
| 7 | US5059654A | Affinity matrices of modified polysaccharide supports | 486 |
| 8 | US6566114B1 | Mannanases | 429 |
| 9 | US20030129192A1 | Compositions and methods for the therapy and diagnosis of ovarian cancer | 308 |
| 10 | US20030124140A1 | Compositions and methods for the therapy and diagnosis of ovarian cancer | 307 |
Citation counts favour older filings simply because they have had more time to accumulate citations within this searched corpus; treat them as a signal of influence on the field, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say about this field
Three patterns emerge from the filing data that matter more to a filing or freedom-to-operate decision than the raw record count.
Leadership is real but not dominant
The leading assignee holds 188 records and the top 5 combined take 14.5% of all 3,831 records in scope; the top 10 reach 24.4%. That leaves the majority of filing activity spread across a long tail of smaller players and single-filing entrants, which is unusual for a field this operationally specific.
Past the surge, not in decline
Filings peaked at 143 in 2020 and eased to 66 by 2024, a -21% change over that three-year window. Several of the historically largest filers show zero output in the latest full year, which reads as a pause in a mature filing programme rather than exit from the space.
Biology claims outnumber process claims
C07K peptide and protein chemistry touches 73.5% of records while B01D separation processes sit at 42.1% and B01J catalysis/process claims at 27.8%. Resin engineering claims are almost always filed alongside molecule-specific claims rather than as standalone unit-operation patents.
Filing is US- and EPO-led
The United States receives the largest single share of designations (988), ahead of the EPO (729) and PCT/WIPO filings (395). Canada, Australia and Israel each carry meaningful but smaller counts, suggesting protection strategy concentrates on the US and European markets first.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to protein chromatography resin selection, with the prior art for and against each one.
Who is filing, and where the field is thinning out
The ranked list runs 100 assignees deep, counted in records rather than raw document filings. Leadership sits with a handful of large biopharma and life-sciences tooling companies, but the field is far from a two-player race.
A single leader, not a monopoly
The top-ranked assignee holds 188 records, more than double the fifth-place holder's 83 and nearly three times the tenth-place holder's 65. That gap at the very top coexists with a shallow drop-off further down the list, meaning the leader's advantage is real but not defensive of the whole field.
Several large filers have gone quiet
A number of the assignees with the deepest historical portfolios show zero filings in the most recent full year, a pattern consistent with mature programmes consolidating existing protection rather than exiting the space. This is worth checking directly before assuming any one of them has stepped back for good, given publication lag.
Co-filing is limited and concentrated
Only 10 co-assignee pairs appear across the dataset, with the strongest pairing linked by 9 shared records. Most filers in this space protect their resin and process claims independently rather than through joint ventures or shared assignments.
| Assignee | Recent year | YoY |
|---|---|---|
| Regeneron Pharmaceuticals Inc | 0 | -100% |
| GE Healthcare Bio-Sciences AB | 0 | — |
| EMD Millipore Corp | 0 | — |
| Genzyme Corporation | 0 | — |
| F. Hoffmann-La Roche AG | 0 | — |
| Merck Patent GmbH | 0 | — |
| UCB Biopharma SPRL | 0 | -100% |
| Genentech, Inc. | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, licensing or new filing strategy.
Map claim scope on the most-cited prior art
The five most-cited records in this corpus, including WO2005052146A2 and WO1999064619A2, anchor a large share of downstream citations. Understanding exactly what they claim is the fastest way to see where new filings still have room.
Explore citation network in EurekaCheck the under-claimed branches before drafting
Alkaline-stability chemistries and resin lifetime validation methods show thinner claim density than the core peptide and separation classes. A first claim there is more likely to clear prior art cleanly than one filed against the crowded C07K core.
Run a white space search in EurekaTrack the quiet incumbents
Several of the largest historical filers show zero output in the latest full year. Whether that reflects portfolio consolidation or a real pause matters for both licensing and freedom-to-operate calls.
Monitor assignee activity in EurekaCommon questions on this landscape
One assignee leads the ranked list with 188 records, more than double the fifth-place holder's 83. The top 5 assignees combined hold 14.5% of all 3,831 records in scope, and the top 10 hold 24.4%, so while there is a clear leader, the majority of filing activity is spread across a long tail of 100 ranked companies. No single company controls enough of the claim space to be described as dominant.
Filings peaked at 143 in 2020 and eased to 66 by 2024, a -21% change over that three-year window, which reads as a return to a lower baseline rather than a field in decline. The 2025 and 2026 figures in any trend chart will look lower still simply because publication typically lags filing by around 18 months, not because activity has stopped. The more complete picture is that this is a mature field past its filing surge, still actively defended by its historic leaders.
C07K, covering peptide and protein chemistry, appears in 73.5% of the 3,831 records in scope, making it the single largest IPC class by a wide margin. C12N genetic engineering (46.2%) and B01D separation processes (42.1%) follow, with B01J catalysis and process claims at 27.8%. Because most records carry more than one IPC code, these shares add up to well over 100%, and resin engineering claims are typically filed alongside molecule-specific biology claims rather than as standalone process patents.
US10071364B2, assigned to Genzyme Corporation and granted in 2018, covers methods of sterilising a chromatography resin by gamma-irradiation while adding an antioxidant agent and/or chelator to offset the binding-capacity loss that irradiation otherwise causes. It also covers the resulting sterilised resin and the chromatography columns built from it. Anyone developing gamma-sterilisation-compatible resin formulations should check this claim's exact scope against their process before assuming freedom to operate.
Based on the IPC composition, alkaline-stability ligand chemistries, high-pressure resin bed engineering, resin lifetime and cleaning-cycle validation methods, and mixed-mode ligand selectivity design all sit outside the densest claim clusters in C07K and C12N. These branches are not empty, but they carry noticeably thinner claim density relative to the core biology and separation classes. A first claim in one of these areas is more likely to clear existing prior art than a filing aimed squarely at the crowded peptide-chemistry core.
Research Protein Chromatography Resin Selection in depth with Eureka
Go past this page: query the whole protein chromatography resin selection corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.